Biochemical scaffolds for regulating mammalian cell function. The biochemical scaffolds include a base liquid medium, a bioenergetic platform and a vibrational platform. The bioenergetic platform includes at least one Krebs cycle modulator and/or neurotransmitter modulator. The vibrational platform includes at least one energy signature component, e.g., an herb. The biochemical scaffold is subjected to harmonic oscillation for a defined, predetermined period of time, wherein the energy signature of the energy signature component is imparted to, captured, replicated, and retained by the liquid medium, and, when the biochemical scaffolds are delivered to and, thus, in communication with biological tissue, the biochemical scaffolds induce specific biochemical activities via the resonant transfer of the retained energy signature to the biological tissue and, hence, endogenous cells thereof.

The present disclosure provides Diels-Alder adducts of chalcone and prenylphenyl moieties capable of modulating the activity of cannabinoid receptors, and to oligomers of flavan-3-ol capable of modulating fat absorption and storage. Such Diels-Alder adducts of chalcone and prenylphenyl moieties or oligomers of flavan-3-ol can optionally be used in combination with other weight management agents, such as anorectic agents, a lipase inhibitors, other cannabinoid receptor modulators, psychotropic agents, insulin sensitizers, stimulants, or satiety agents, as well as to methods of use thereof such as treating or preventing weight gain or obesity, promoting weight loss, appetite suppression, modifying satiety, or the like.

The present disclosure provides Diels-Alder adducts of chalcone and prenylphenyl moieties capable of modulating the activity of cannabinoid receptors, and to oligomers of flavan-3-ol capable of modulating fat absorption and storage. Such Diels-Alder adducts of chalcone and prenylphenyl moieties or oligomers of flavan-3-ol can optionally be used in combination with other weight management agents, such as anorectic agents, a lipase inhibitors, other cannabinoid receptor modulators, psychotropic agents, insulin sensitizers, stimulants, or satiety agents, as well as to methods of use thereof such as treating or preventing weight gain or obesity, promoting weight loss, appetite suppression, modifying satiety, or the like.

A cannabidiol (CBD) gelled delivery system comprising: a rheology modifier; an emollient; and one or more cannabidiols selected from the group consisting of a cannabidiol broad spectrum oil, a cannabidiol full spectrum oil, or a cannabidiol isolate. A CBD emulsified delivery system comprising: a rheology modifier; an emollient; a polyglyceryl ester surfactant; and one or more cannabidiols selected from the group consisting of a cannabidiol broad spectrum oil, a cannabidiol full spectrum oil, or a cannabidiol isolate. For such delivery systems, the cannabidiols contain less than 0.3 wt. % of tetrahydrocannabinol (THC) or the cannabidiols are substantially free of THC. An active gelled delivery system a rheology modifier; an emollient; and one or more actives. An active emulsified delivery system comprising: a rheology modifier; an emollient; a polyglyceryl ester surfactant; and one or more actives.

Disclosed are a Chinese medicinal composition for preventing or treating cardiovascular and cerebrovascular diseases and/or dementia, and a preparation method and use thereof. The composition is prepared from the following medical raw materials in parts by weight: 1 part of ginseng, 0.8-1.5 parts of ginkgo leaf and 0.018-0.030 part of stigma croci.

Disclosed are a Chinese medicinal composition for preventing or treating cardiovascular and cerebrovascular diseases and/or dementia, and a preparation method and use thereof. The composition is prepared from the following medical raw materials in parts by weight: 1 part of ginseng, 0.8-1.5 parts of ginkgo leaf and 0.018-0.030 part of stigma croci.

Disclosed are a Chinese medicinal composition for preventing or treating cardiovascular and cerebrovascular diseases and/or dementia, and a preparation method and use thereof. The composition is prepared from the following medical raw materials in parts by weight: 1 part of ginseng, 0.8-1.5 parts of ginkgo leaf and 0.018-0.030 part of stigma croci.

A method of preventing or treating an inflammatory disease including diabetes type 1 and type 2 in a subject in need thereof is provided. Also provided are pharmaceutical compositions, articles and foods for the treatment of an inflammatory disease.

A method of preventing or treating an inflammatory disease including diabetes type 1 and type 2 in a subject in need thereof is provided. Also provided are pharmaceutical compositions, articles and foods for the treatment of an inflammatory disease.

The present disclosure provides a preparation method of a Kaixinsan powder, including the following steps: pulverizing Radix Polygalae, Rhizoma Acori Graminei, ginseng, and Poria into a fine powder separately; and mixing each fine powder evenly in sequence according to a backing register method to obtain the Kaixinsan powder; where in the Kaixinsan powder, the fine powders each are required to pass through an 80-mesh sieve, and at least 95 wt% of each of the fine powders passes through a 100-mesh sieve. In the present disclosure, the fine powder of each medicinal material is capable of being mixed evenly, and has desirable dissolution effect and stability; and the Kaixinsan powder meets requirements for traditional Chinese medicine powders stipulated in Chinese Pharmacopoeia 2020 edition.